What does Conrad Pharma do?

Conrad Pharma is a pharmacy in Oudenaarde. Private Limited, started on 23 July 2013, 1 establishment.

What is the address of Conrad Pharma?

The registered office of Conrad Pharma is located at Diependale 8, 9700 Oudenaarde.

Is Conrad Pharma still active?

Yes. According to the CBE (30 October 2026) Conrad Pharma is active, legal situation “Normale toestand”, started on 23 July 2013.

Is Conrad Pharma registered on Peppol?

Yes, Conrad Pharma is registered on the Peppol network with ID 0208:0536875697.

What is the enterprise number of Conrad Pharma?

The enterprise number of Conrad Pharma is BE0536875697.

When was Conrad Pharma founded?

Conrad Pharma was founded on 23 July 2013.

Who are the directors of Conrad Pharma?

According to the 2025 annual accounts, the directors of Conrad Pharma are: Philippe Verzele, Vanessa Pluym.

Is Conrad Pharma a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 23 July 2013; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did Conrad Pharma make in 2025?

Conrad Pharma posted a profit after taxes of € 199,229 in financial year 2025.

What is the revenue of Conrad Pharma?

As a small company, Conrad Pharma is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 504,793.

How much does an employee at Conrad Pharma earn?

The average wage cost per full-time employee at Conrad Pharma was € 49,200 in 2025: staff costs of € 123,052 for 2.5 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does Conrad Pharma have?

According to the 2025 annual accounts, Conrad Pharma has 2.5 full-time equivalents (FTE).

Conrad Pharma (Private Limited) - Oudenaarde

Dossier Conrad Pharma, printed on 30 October 2026 from databakkes.be/en/0536875697/conrad-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 42 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

Conrad Pharma from Oudenaarde, company number BE0536875697, closed financial year 2025 with a result of € 199,229 after tax. For that financial year Conrad Pharma recorded a gross margin of € 504,793 and equity of € 1.1 million. Compared with financial year 2024, the result moved from € 188,587 to € 199,229. Profitable, and profit is growing. The company holds a healthy buffer. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on August 28, 2026.

What it is worth Healthy

€ 1.1 million

▼ 4% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 199,229

▲ 6% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 185,864

▲ 77% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 250,000 paid out

More than the year’s profit went to the shareholders; reserves fell.

People and assets in 2025

Full-time equivalents

2.5

▲ 0.2 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 123,052

▲ 19% vs 2024

€ 49,200 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 1,317

▼ 82% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 11 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 3.2 million

▼ 20% vs 2024

€ 280,431 is repaid this year. At this pace the long-term loan is gone in ≈ 11 years.

Owed to suppliers

€ 64,249

▲ 5% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 79,549

▲ 59% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 474,210 Gross margin 2022: € 474,210 First fiscal year in the series	€ 450,285 Gross margin 2023: € 450,285 ▼ 5% vs 2022 (€ 474,210) Unfavourable step	€ 429,970 Gross margin 2024: € 429,970 ▼ 5% vs 2023 (€ 450,285) Unfavourable step	€ 504,793 Gross margin 2025: € 504,793 ▲ 17% vs 2024 (€ 429,970) Favourable step	▲ 17%
Profit after taxes	€ 295,505 Profit after taxes 2022: € 295,505 First fiscal year in the series	€ 192,287 Profit after taxes 2023: € 192,287 ▼ 35% vs 2022 (€ 295,505) Unfavourable step	€ 188,587 Profit after taxes 2024: € 188,587 ▼ 2% vs 2023 (€ 192,287) Unfavourable step	€ 199,229 Profit after taxes 2025: € 199,229 ▲ 6% vs 2024 (€ 188,587) Favourable step	▲ 6%
Equity	€ 895,973 Equity 2022: € 895,973 First fiscal year in the series	€ 1,055,333 Equity 2023: € 1,055,333 ▲ 18% vs 2022 (€ 895,973) Favourable step	€ 1,183,920 Equity 2024: € 1,183,920 ▲ 12% vs 2023 (€ 1,055,333) Favourable step	€ 1,133,149 Equity 2025: € 1,133,149 ▼ 4% vs 2024 (€ 1,183,920) Unfavourable step	▼ 4%
Total debts	€ 2,560,221 Total debts 2022: € 2,560,221 First fiscal year in the series	€ 2,466,490 Total debts 2023: € 2,466,490 ▼ 4% vs 2022 (€ 2,560,221) Favourable step	€ 4,470,471 Total debts 2024: € 4,470,471 ▲ 81% vs 2023 (€ 2,466,490) Unfavourable step	€ 3,875,517 Total debts 2025: € 3,875,517 ▼ 13% vs 2024 (€ 4,470,471) Favourable step	▼ 13%
Cash	€ 94,833 Cash 2022: € 94,833 First fiscal year in the series	€ 166,139 Cash 2023: € 166,139 ▲ 75% vs 2022 (€ 94,833) Favourable step	€ 104,724 Cash 2024: € 104,724 ▼ 37% vs 2023 (€ 166,139) Unfavourable step	€ 185,864 Cash 2025: € 185,864 ▲ 77% vs 2024 (€ 104,724) Favourable step	▲ 77%
Land & buildings	€ 12,315 Land & buildings 2022: € 12,315 First fiscal year in the series	€ 10,816 Land & buildings 2023: € 10,816 ▼ 12% vs 2022 (€ 12,315) Unchanged	€ 280,827 Land & buildings 2024: € 280,827 ▲ € 270,010 vs 2023 (€ 10,816) Unchanged	€ 265,578 Land & buildings 2025: € 265,578 ▼ 5% vs 2024 (€ 280,827) Unchanged	▼ 5%
Retained profit	€ 795,973 Retained profit 2022: € 795,973 First fiscal year in the series	€ 955,333 Retained profit 2023: € 955,333 ▲ 20% vs 2022 (€ 795,973) Favourable step	€ 1,083,920 Retained profit 2024: € 1,083,920 ▲ 13% vs 2023 (€ 955,333) Favourable step	€ 1,033,149 Retained profit 2025: € 1,033,149 ▼ 5% vs 2024 (€ 1,083,920) Unfavourable step	▼ 5%
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 32,927 Dividend 2023: € 32,927 Unchanged (€ 0) Unchanged	€ 60,000 Dividend 2024: € 60,000 ▲ 82% vs 2023 (€ 32,927) Unchanged	€ 250,000 Dividend 2025: € 250,000 ▲ € 190,000 vs 2024 (€ 60,000) Unchanged	▲ € 190,000
Bank debt	€ 2,073,146 Bank debt 2022: € 2,073,146 First fiscal year in the series	€ 1,926,564 Bank debt 2023: € 1,926,564 ▼ 7% vs 2022 (€ 2,073,146) Favourable step	€ 4,014,813 Bank debt 2024: € 4,014,813 ▲ 108% vs 2023 (€ 1,926,564) Unfavourable step	€ 3,212,549 Bank debt 2025: € 3,212,549 ▼ 20% vs 2024 (€ 4,014,813) Favourable step	▼ 20%
Balance sheet total	€ 3,456,193 Balance sheet total 2022: € 3,456,193 First fiscal year in the series	€ 3,521,823 Balance sheet total 2023: € 3,521,823 ▲ 2% vs 2022 (€ 3,456,193) Unchanged	€ 5,654,391 Balance sheet total 2024: € 5,654,391 ▲ 61% vs 2023 (€ 3,521,823) Unchanged	€ 5,008,666 Balance sheet total 2025: € 5,008,666 ▼ 11% vs 2024 (€ 5,654,391) Unchanged	▼ 11%
Employees (FTE)	1.9 Employees (FTE) 2022: 1.9 First fiscal year in the series	2.8 Employees (FTE) 2023: 2.8 ▲ 0.9 vs 2022 (1.9) Unchanged	2.3 Employees (FTE) 2024: 2.3 ▼ 0.5 vs 2023 (2.8) Unchanged	2.5 Employees (FTE) 2025: 2.5 ▲ 0.2 vs 2024 (2.3) Unchanged	▲ 0.2

Key figures of Conrad Pharma, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Conrad Pharma?

What happened at Conrad Pharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 28, 2026 New annual accounts for financial year 2025: profit of € 199,229 (▲ 6% vs 2024). filed late Source: NBB ↗
Aug 1, 2013 New establishment in Maarkedal. KBO
Jul 23, 2013 Start of the company according to the CBE. KBO

In short

From € 295,505 profit in 2022 to € 199,229 profit in 2025.

Paid € 269,680 in corporate taxes since 2022.

Best year ever: 2022, with € 295,505 profit.

On average € 201,900 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

Philippe Verzele

Vanessa Pluym

Conrad Pharma

Verzele Pharma 100%

Decaphar 100%

Verzele Pharma Zwalm 100%

Geva Pharma 100%

Behind Conrad Pharma are Philippe Verzele and Vanessa Pluym. It owns 100% of Verzele Pharma, 100% of Decaphar, 100% of Verzele Pharma Zwalm and 100% of Geva Pharma itself.

Directors

According to the 2025 annual accounts

Philippe Verzele

Director

Also active at: GEVA PHARMA, VERZELE PHARMA ZWALM, DECAPHAR, VERZELE PHARMA

Vanessa Pluym

Director

Also active at: GEVA PHARMA, VERZELE PHARMA ZWALM, DECAPHAR, VERZELE PHARMA

Establishments

Establishment units

Physical locations of this company

Registered office

Diependale 8

9700 Oudenaarde

2.223.673.827

Nukerkestraat 2

9681 Maarkedal

Active since 1 August 2013

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 4 companies are registered at this address.

All companies at this address →

GEVA PHARMA same network

€ 229,726 gross margin · 2025

VERZELE PHARMA ZWALM same network

€ 76,445 gross margin · 2025

DECAPHAR same network

€ 300,895 gross margin · 2025

VERZELE PHARMA same network

€ 186,426 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0536.875.697

VAT number

BE 0536.875.697

Registered office

Diependale 8, 9700 Oudenaarde

Names & denominations

Conrad Pharma

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

23 July 2013

Peppol

Active · Active since 5 Oct 2026

Activities · NACE

Detailhandel in farmaceutische producten

Overige zakelijke dienstverlening, neg

View on CBE Public ↗ Annual accounts (NBB) ↗

Conrad Pharma

Warning lights

Financials

What happened to Conrad Pharma?

Management

Directors

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions